|Mr. Jay T. Flatley||Chairman & Acting CEO||1.03M||N/A||1953|
|Mr. Zachariah Serber Ph.D.||Co-Founder & Director||353.49k||N/A||1975|
|Ms. Enakshi Singh||Chief Financial Officer||390.3k||N/A||1978|
|Mr. Dmitriy Ryaboy||Chief Technology Officer||N/A||N/A||N/A|
|Mike Dulin||Director of Communications||N/A||N/A||N/A|
|Mr. Lincoln Germain||Chief Commercial Officer||N/A||N/A||N/A|
|Mr. Subodh S. Deshmukh||Chief Devel. Officer||N/A||N/A||N/A|
|Mr. Devin Scannell||Sr. VP of Drug Discovery||N/A||N/A||N/A|
|Mr. Duane Valz J.D.||Sec.||N/A||N/A||N/A|
|Ms. Mina Kim||Corp. Sec.||N/A||N/A||1974|
Zymergen Inc. design, develop, and commercialize microbes, molecules, and materials. It offers an automation solution comprising reconfigurable automation carts, a modular hardware building blocks that allow for assembly of work cells customized for the particular needs of a lab; and automation control software, a cloud-based software used to control integrated automation systems. It serves electronics, packaging, healthcare, agriculture, and other industries. Zymergen Inc. was incorporated in 2013 and is based in Emeryville, California.
Zymergen Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.